A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer
![](https://researchstudies.cuanschutz.edu/Content/images/study-category-images/cancer.jpg)
Details
Age
Adult
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
![Photograph of Tejas Patil](https://som.ucdenver.edu/FIMS/Content/faculty/24489/CU-Doctors-24489.jpg)
Tejas Patil
Study ID
Protocol Number: 23-1245
More information available at ClinicalTrials.gov: NCT04844073
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers